Zai Lab Limited Stock Price, News & Analysis

Welcome to our dedicated page for Zai Lab news (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab stock.

Zai Lab Limited (ZLAB) is a research-based, commercial-stage biopharmaceutical company based in China and the United States, with a focus on oncology, immunology, neuroscience, and infectious disease. The Zai Lab news feed on Stock Titan aggregates company announcements, clinical updates, regulatory milestones, and financial disclosures that the company releases through channels such as Business Wire and SEC filings.

Investors and followers of ZLAB stock can use this page to review news on Zai Lab’s global pipeline, including progress of assets like zocilurtatug pelitecan (zoci), a DLL3-targeted antibody-drug conjugate for extensive-stage small cell lung cancer and other neuroendocrine carcinomas, and ZL-1503, an IL-13/IL-31R bispecific antibody for atopic dermatitis. Updates on other oncology and immunology programs, such as ZL-6201, ZL-1222, and ZL-1311, also appear in company press releases.

The news stream highlights regulatory developments in Greater China, including National Medical Products Administration (NMPA) approvals and National Reimbursement Drug List (NRDL) decisions for products in Zai Lab’s commercial portfolio. Recent examples include announcements about COBENFY for schizophrenia and AUGTYRO for ROS1-positive non-small cell lung cancer and NTRK-positive solid tumors, as well as renewals and coverage decisions for VYVGART, NUZYRA, and ZEJULA.

In addition, this page surfaces Zai Lab’s financial result releases, conference call notices, and participation in healthcare and investor conferences. These items provide context on revenue trends, R&D spending, and the company’s dual-engine strategy combining a China commercial business with a global innovation platform. Bookmark this page to quickly access ZLAB-related news, organized in one place for efficient review of the company’s ongoing clinical, regulatory, and corporate developments.